

Armand Keating, MD, FRCP(C)

Professor of Medicine
Division of Hematology, Department of Medicine

Professor, Institute of Biomaterials and Biomedical Engineering,

University of Toronto
Director, Cell Therapy
Program Princess Margaret Hospital
University Health Network.

Office Address:

Princess Margaret Hospital
Suite 5-303
610 University Avenue,
Toronto ON. M5G 2M9
416 946 4595
armand.keating@uhn.ca
<http://www.celltherapy.ca/>



Armand Keating, MD, FRCP(C) is Professor of Medicine and also a Professor in the Institute of Biomaterials and Biomedical Engineering, at the University of Toronto, Toronto, Canada. For the past 19 years he was Director, Division of Hematology and Epstein Chair in Cell Therapy and Transplantation at the University of Toronto. He is Director of the Cell Therapy Program and the Orsino Cell Therapy Translational Research Laboratory at Princess Margaret Cancer Centre and a Senior Scientist in Experimental Therapeutics at the Toronto General Research Institute. He obtained the MD degree from the University of Ottawa, completed residencies in internal medicine and hematology at the University of Toronto and a research fellowship at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, Washington. He was a Cancer Research Scientist of the National Cancer Institute of Canada for 10 years and upon his return to Toronto established the largest stem cell transplant program in Canada. He was Chief of Medical Services and Head, Department of Medical Oncology and Hematology at Princess Margaret Hospital/Ontario Cancer Institute in Toronto for a decade. He is listed in Best Doctors in Canada and the US. Over the past 7 years he established the largest and most active cell therapy program in Canada involving local, national and international collaborators. He is the recipient of a multimillion dollar Canada Foundation for Innovation Award for a regional Center for Cell and Vector Production in Toronto. Dr. Keating has been active in the American Society of Hematology (ASH) and was President of ASH in 2012. He is a past president of the American Society for Blood and Marrow Transplantation and was Chair of the Steering Committee for Cell-Based Therapy of the National Heart, Lung, and Blood Institute, US National Institutes of Health. He was also Chair of the Medical and Scientific Committee of The Leukemia & Lymphoma Society and a member of its Board of Directors for 8 years. He heads the Clinical Translation Committee of the International Society for Stem Cell Research (ISSCR). He is a member of the Canadian Stem Cell Network and is on the advisory

boards of the Centre for Commercialization of Regenerative Medicine, the Argentine Stem Cell Consortium and the Andalusian Advanced Therapies Program. He is on numerous editorial boards of scholarly journals, and is a Co-Editor of Bone Marrow Transplantation and Associate Editor of Biology of Blood and Marrow Transplantation. Dr. Keating's clinical and research interests focus on cell-based tissue regeneration, anti-cancer cell therapy, blood and marrow transplantation, and leukemia, lymphoma. He has conducted laboratory, translational and clinical research in these areas, and particularly on the biology and clinical application of mesenchymal stromal cells. He has authored over 370 publications.